Sir, Antibiotic research has focused on discovering agents with activity against MDR pathogens (e.g. ESKAPE pathogens 1 ), including VRE, which along with Staphylococcus aureus are commonly isolated from healthcare-associated infections.
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2 Several new agents have been approved for the treatment of skin and skin structure infections caused by MRSA and enterococci, including oxazolidinones (linezolid and tedizolid), lipoglycopeptides (oritavancin, dalbavancin and telavancin), a cyclic lipopeptide (daptomycin), a glycylcycline (tigecycline) and an anti-MRSA cephalosporin (ceftaroline). Lipoglycopeptides, though active against vancomycin-susceptible enterococci (VSE), have variable activity against VRE, with oritavancin being the sole agent maintaining potent activity against VanA-type VRE. 3 We report here a direct comparison of the in vitro activity of lipoglycopeptides and other skin agents against vancomycinsusceptible and -resistant Enterococcus faecalis (VSEfa and VREfa) and Enterococcus faecium (VSEfm and VREfm). Comparative evaluations included MIC and MBC determinations and time-kill kinetics. Since variation in inoculum density has been shown to impact the activity of several of these agents against S. aureus, 4, 5 time-kill kinetics were assessed at both standard and high inoculum densities.
The evaluated isolates consisted of 74 random non-duplicate clinical isolates of VSEfa, VREfa, VSEfm and VREfm from the Micromyx repository (Kalamazoo, MI, USA) and The Medicines Company (Ville Saint Laurent, Quebec, Canada). VanA-phenotype (vancomycin and teicoplanin resistant) and VanB-phenotype (vancomycin resistant and teicoplanin susceptible) VRE were selected based on prior glycopeptide susceptibility test history. Agents were handled per CLSI (formerly NCCLS) guidelines and had results within CLSI quality control ranges during testing.
6 Evaluations of lipoglycopeptides incorporated polysorbate 80 at a final concentration of 0.002% (v/v). MIC and MBC values were determined in accordance with standard CLSI methods.
6-8 The time-kill kinetics of select isolates (one per phenotype evaluated) at standard inoculum (5 % 10 5 cfu/ mL) and high inoculum (5 % 10 7 cfu/mL) were determined as described by Arhin et al.
9 using a method derived from the CLSI 8 for agents at their fC max (calculated from the respective prescribing information as 16 mg/L for oritavancin, dalbavancin, linezolid, vancomycin and ceftaroline, 8 mg/L for telavancin, 4 mg/L for daptomycin and 1 mg/L for tedizolid).
The activity of the tested agents against enterococci is summarized by species and phenotype in Table 1 . Among E. faecalis, VSEfa were susceptible to all agents with the lipoglycopeptides having the most potent activity by MIC 90 . Ceftaroline and oritavancin were the only consistently bactericidal agents against VSEfa based on the proportion of isolates with MBC:MIC ratios of 4. Based on MIC 90 , oritavancin, daptomycin, linezolid, tedizolid and ceftaroline maintained potent activity against VanA VREfa. Ceftaroline maintained bactericidal activity against VanA VREfa, while the other agents typically had MBC:MIC ratios .4.
Against VSEfm and VREfm (VanA and VanB phenotypes), oritavancin was the most potent agent evaluated based on MIC 90 . All agents, excluding ceftaroline, which was largely inactive against E. faecium, had potent activity against VSEfm by MIC 90 . Oritavancin, daptomycin, linezolid and tedizolid maintained potent activity against VREfm. Oritavancin was 16-fold more potent by MIC 90 than the comparator lipoglycopeptides against VREfm. Against VSEfm, oritavancin and daptomycin were the only consistently bactericidal agents based on the proportion of isolates with MBC:MIC ratios of 4. Daptomycin maintained bactericidal activity by MBC:MIC ratio against VanA and VanB VREfm.
Consistent trends in bactericidal activity were apparent for each agent by time-kill at fC max across the evaluated E. faecalis (one isolate each of VSEfa and VanA VREfa) and E. faecium (one isolate each of VSEfm, VanA VREfm and VanB VREfm) isolates. At the standard inoculum density, oritavancin and daptomycin were rapidly bactericidal with 3 log killing typically achieved within 0.25 and 4 h, respectively, with singular exceptions (4 h for oritavancin and 1 h for daptomycin against the VanA VREfa isolate). Telavancin was typically bactericidal, with 3 log killing observed at 24 h at the standard inoculum density with the exception of the VanB VREfm isolate, as was ceftaroline for E. faecalis but not E. faecium. Vancomycin, dalbavancin, tedizolid and linezolid did not achieve 3 log killing at the standard inoculum density for any of the V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. evaluated E. faecalis or E. faecium isolates. Only oritavancin maintained bactericidal activity at the high inoculum density, with similar kill kinetics to those observed at the standard inoculum density.
Few available agents exist for treating VRE infections despite their prevalence and associated mortality and morbidity.
10 Among agents with activity against enterococci, oritavancin, daptomycin, linezolid and tedizolid maintained potent activity against VanA/ VanB VRE isolates. Both daptomycin and oritavancin exhibited rapid bactericidal activity at fC max against VSE and VRE at standard inoculum densities, but only oritavancin maintained rapid bactericidal activity at high inoculum densities. Maintaining bactericidal activity at high inoculum density may be relevant in the context of enterococcal infections where dense foci of pathogens may be present locally (e.g. endocarditis and osteomyelitis). Thus, further investigation into the clinical utility of both daptomycin and oritavancin against VRE infections is warranted.
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c For the evaluated VSEfm isolate at standard inoculum density, time to 2.9 log kill was reported (based on the starting inoculum of 4.9 log cfu/mL and a lower limit of detection of 2 log cfu/mL for the assay). Mycoplasma genitalium is a common sexually transmissible pathogen that causes urethritis and cervicitis with symptoms and signs similar to Chlamydia trachomatis infection.
1 There is strong evidence that M. genitalium also causes salpingitis and tubal factor infertility.
2 The first-line recommended treatment is an extended azithromycin regimen (1.5 g; 500 mg on day 1, followed by 250 mg on days 2-5).
3 However, increasing rates of treatment failures with this regimen of azithromycin have been reported. 4 In case of azithromycin treatment failure, moxifloxacin has shown to be effective, but in recent years treatment failures have been reported. 5, 6 In spite of in vitro susceptibility to doxycycline, clinical trials have shown a low rate of clinical cure (30%-40%).
7,8 Pristinamycin (1 g, three to four times daily for 10 days) treatment is a third option with occasional success. 6 However, there is an urgent need for alternative active antimicrobials in MDR M. genitalium infections.
A man who had sex with men attended the STD clinic because of urethral symptoms. He had a microscopically, culture and PCR-verified gonococcal infection and was treated with 500 mg of ceftriaxone intramuscularly and 2 g of azithromycin orally. A test for C. trachomatis was negative, but his M. genitalium test was positive. Test of cure was negative for Neisseria gonorrhoeae, but positive for M. genitalium. His urethritis symptoms had ceased and he remained asymptomatic. Because of a glucose-6-phosphate-dehydrogenase deficiency, the patient could not be treated with moxifloxacin.
During the following months, he was treated several times with antibiotics due to different infections. Test results and the timeline of antibiotic treatments are presented in Table 1 . Because of symptoms and signs of a perineal abscess with an anal fistula he had surgery and was treated with imipenem/cilastatin. Retrospectively, lymphogranuloma venereum was assumed to be the cause of the anal symptoms; however, this was not suspected or tested for initially. Consequently, 4 months later, treatment with doxycycline (100 mg twice daily for 14 days) was prescribed. However, a rectal test for C. trachomatis was negative.
A first void urine (FVU) PCR test, 6 months after the first M. genitaliumpositive test, analysed at the Statens Serum Institut (SSI), Copenhagen, was M. genitalium-positive with a mutation in region V of the 23SrRNA gene (A2058T). He was then treated with pristinamycin (1 g three times daily for 10 days) without clearance. His partner living and tested abroad was M. genitalium-negative according to the patient.
During the following year the patient experienced weight loss, fatigue and chronic herpes simplex virus type 2 anogenital ulcers. Eventually he decided to be tested for HIV infection (which he had declined to do earlier) and he was diagnosed with AIDS. Antiretroviral treatment as well as treatment with trimethoprim/sulfamethoxazole was initiated. He gained weight, is currently well and with undetectable HIV-1 RNA.
Owing to a positive syphilis antibody test, treatment with doxycycline for 30 days was prescribed. FVU tests for M. genitalium were repeatedly positive. A urine sample analysed at the SSI 17 months after the first known positive test, showed persisting macrolide resistance now with both A2058G and A2058T mutations present. However, MgPa typing revealed only one strain with the same strain type as initially.
Despite being asymptomatic, the patient was highly motivated to undergo treatment. This was 2 years after the first verified positive test. Spectinomycin, an aminocyclitol aminoglycoside, only used as an alternative treatment for N. gonorrhoeae, is theoretically active against M. genitalium and a single experiment showing an MIC of 4 mg/L for the macrolide susceptible G37 type strain of M. genitalium supported its use (J. S. Jensen, unpublished data). Spectinomycin hydrochloride (Trobicin V R ) (2 g) was administrated intramuscularly once daily for 7 days. An FVU test taken on the first treatment day was an M. genitalium-positive A2058G mutation. FVU samples were collected by the patient on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26 and sent by post weekly to the SSI for analysis as previously described.
9 From the fourth day of treatment all samples were negative for M. genitalium. No adverse events were reported. This is the first known report of spectinomycin treatment against M. genitalium. An extended treatment regimen was used because of lack of previous experience and the known slow replication rate of M. genitalium. The rapid response with negative tests in this patient is in line with a treatment study with azithromycin and moxifloxacin. 9 In that study a late occurrence (after 2-3 weeks) of resistant M. genitalium strains occurred in a few cases.
9 A late follow-up at 65 days after treatment was M. genitaliumpositive (FVU). Fifty days after treatment, the patient had unprotected sexual intercourse with his partner living abroad, who had neither been tested nor treated for M. genitalium. Thus, reinfection was highly likely. Future studies are needed to determine whether a shorter treatment period would be sufficient.
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